Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial

Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III and IV NSCLC with a histologicall...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stathopoulos, G P, Dimitroulis, J, Antoniou, D, Katis, C, Tsavdaridis, D, Armenaki, O, Marosis, C, Michalopoulou, P, Grigoratou, T, Stathopoulos, J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2005
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361499/
https://ncbi.nlm.nih.gov/pubmed/16251879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602827
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados